Embecta Corp. Common Stock EMBC

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Con 173 acciones de EMBC (USD 997,34) habrías recibido USD 55,36 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 22 sept

  EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

  Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.

  

• GlobeNewswire Inc. 31 ago

  embecta to Participate in Investor Events

  Embecta Corp. (EMBC) announced that management will participate in investor events at the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 on September 10, 2026, where they will host fireside chats and one-on-one investor meetings.

  

• GlobeNewswire Inc. 10 ago

  EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

  Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

  

• GlobeNewswire Inc. 7 ago

  ZILLOW DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zillow Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - Z, ZG

  Rosen Law Firm is reminding investors in Zillow Group, Embecta Corp, and GoDaddy Inc. of upcoming lead plaintiff deadlines in securities class actions. The Zillow lawsuit alleges the company made false statements regarding its Redfin agreement and antitrust risks. Investors with losses exceeding $100K are encouraged to contact the firm before the respective deadlines.

  

• GlobeNewswire Inc. 7 ago

  Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

  Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its third quarter fiscal 2026 financial results on August 7, 2026. The company hosted a conference call and webcast for analysts and investors to discuss the earnings.